Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives $42.67 Average PT from Brokerages

Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) have received a consensus recommendation of "Buy" from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $42.67.

SRRK has been the subject of a number of recent research reports. Wedbush reiterated an "outperform" rating and set a $50.00 price target on shares of Scholar Rock in a research note on Wednesday, June 18th. Lifesci Capital upgraded shares of Scholar Rock to a "strong-buy" rating in a research report on Tuesday, June 3rd.

Scholar Rock Stock Up 6.2%

Shares of SRRK stock traded up $2.39 during trading on Wednesday, reaching $41.15. The company's stock had a trading volume of 2,088,744 shares, compared to its average volume of 1,308,299. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.25 and a quick ratio of 10.25. The company has a market capitalization of $3.91 billion, a price-to-earnings ratio of -16.26 and a beta of 0.33. The stock's 50-day moving average price is $33.09 and its 200 day moving average price is $35.09. Scholar Rock has a 1-year low of $6.76 and a 1-year high of $46.98.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period last year, the firm posted ($0.59) EPS. On average, research analysts anticipate that Scholar Rock will post -2.42 EPS for the current year.

Insider Buying and Selling

In other Scholar Rock news, Director Michael Gilman sold 3,375 shares of the stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $29.72, for a total value of $100,305.00. Following the completion of the sale, the director owned 55,216 shares of the company's stock, valued at $1,641,019.52. This trade represents a 5.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mo Qatanani sold 24,066 shares of the firm's stock in a transaction that occurred on Tuesday, July 8th. The stock was sold at an average price of $34.44, for a total transaction of $828,833.04. Following the sale, the insider directly owned 115,495 shares of the company's stock, valued at $3,977,647.80. The trade was a 17.24% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 87,518 shares of company stock valued at $2,820,298. 13.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Scholar Rock

Hedge funds have recently added to or reduced their stakes in the business. E. Ohman J or Asset Management AB lifted its stake in Scholar Rock by 12.9% in the second quarter. E. Ohman J or Asset Management AB now owns 64,568 shares of the company's stock valued at $2,287,000 after buying an additional 7,383 shares during the last quarter. Rhumbline Advisers lifted its stake in Scholar Rock by 6.6% in the first quarter. Rhumbline Advisers now owns 120,752 shares of the company's stock valued at $3,882,000 after buying an additional 7,491 shares during the last quarter. Strs Ohio bought a new stake in Scholar Rock in the first quarter valued at $77,000. Intech Investment Management LLC lifted its stake in Scholar Rock by 60.9% in the first quarter. Intech Investment Management LLC now owns 56,784 shares of the company's stock valued at $1,826,000 after buying an additional 21,483 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Scholar Rock by 25.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company's stock valued at $5,460,000 after buying an additional 34,594 shares during the last quarter. Institutional investors and hedge funds own 91.08% of the company's stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.